Iohexol
From Wikipedia, the free encyclopedia
 |
|
|
Iohexol
|
|
| Systematic (IUPAC) name | |
| 5-(acetyl-(2,3-dihydroxypropyl)amino)-N,N'-bis (2,3-dihydroxypropyl)-2,4,6-triiodo-benzene-1,3- dicarboxamide |
|
| Identifiers | |
| CAS number | |
| ATC code | V08 |
| PubChem | |
| Chemical data | |
| Formula | C19H26I3N3O9 |
| Mol. mass | 821.138 g/mol |
| SMILES | search in , |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | Low |
| Metabolism | Nil |
| Half life | Variable |
| Excretion | Renal, unchanged |
| Therapeutic considerations | |
| Pregnancy cat. |
B(US) |
| Legal status |
℞ Prescription only |
| Routes | Intrathecal, intravascular, oral, intracavital |
Iohexol is a contrast agent, sold under the trade name Omnipaque. It is available in various concentrations, from 140 to 350 milligrams of iodine per milliliter. Omnipaque 350 is commonly used as a contrast agent during coronary angiography.
The osmolality of iohexol ranges from 322 mOsm/kg—approximately 1.1 times that of blood plasma—to 844 mOsm/kg, almost three times that of blood.[1] Despite this difference, iohexol is still considered a low-osmolality contrast agent; the osmolality of older agents, such as diatrizoate, may be more than twice as high.[2]
[edit] References
- ^ GE Healthcare (May 2006). Omnipaque (Iohexol) injection. Product label. DailyMed. U.S. National Library of Medicine. Retrieved on March 28, 2007.
- ^ Amersham Health (April 2006). Hypaque (Diatrizoate Meglumine and Diatrizoate Sodium) injection, solution. Product label. DailyMed. U.S. National Library of Medicine. Retrieved on March 29, 2007.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
